

Cover Story
It's possible that molecular testing is doing a lot of good, pinpointing cancer therapies that are most likely (or least likely) to work.
In Brief


Trending Stories
- Caught in the crossfire: The critical threats facing cancer centers, research, and patient care
- Columbia’s cancer center becomes collateral damage in Trump’s war on antisemitism
- In the Headlines: Could “flooding the zone” drown NIH and cancer centers?
- FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- In the Headlines: What are Jay Bhattacharya’s plans for NIH?
- The University of Rochester Wilmot Cancer Institute earns NCI Cancer Center designation